AUG 26·SEC EDGARLow
Robertson Stephen P. sold $356K of AUPH
Robertson Stephen P. (Chief Legal Officer) sold 20,975 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 ($0.36M total) on 2026-08-21.
StockNASDAQ · US · USDHealthcare · Biotechnology
$AUPH
Aurinia Pharmaceuticals Inc.
alphai earnings readThree months ended June 30, 2026 · AUG 6Aurinia reported three-month total revenue of $83.2 million, up 19%, and net income of $37.4 million, up 74%, while reiterating 2026 total revenue guidance of $315 million to $325 million.Verdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $AUPHvia TradingView
AI sentiment · 7d2 articles
- Bullish
- 1
- Neutral
- 0
- Bearish
- 1
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $356K 1 txs
Robertson Stephen P.1× · $356K
10b5-1 share of filings0%
Top stories · $AUPHMore →
AUG 22·stocktitan.net
Aurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes
Aurinia Pharmaceuticals (AUPH) officer Stephen P. Robertson plans to sell 47,000 shares under Rule 144 to cover tax obligations from vesting performance stock units, with the sale expected to occur on or after 08/21/2026. The transaction will be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
AUG 21·simplywall.st
Aurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain
Aurinia Pharmaceuticals (AUPH) settled with Teva, delaying generic competition for voclosporin until 2036. AUPH shares rose 13.77% in 7 days, 12.51% YTD, closing at $17.27. Revenue is projected to grow 16-21% this year, with EPS potentially doubling. The stock is considered 17.8% undervalued with a fair value of $21.00, but faces risks like concentration around Lupkynis.
AUPH sentiment & insider activity
Over the past 7 days, alphai's AI scored 2 news stories mentioning AUPH (Aurinia Pharmaceuticals Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent AUPH coverage spans financial news, insider activity and market movers.
In the last 30 days, AUPH insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($356K). The most active reporter was Robertson Stephen P., Chief Legal Officer, with 1 filing.
What's driving AUPH
Insider sale may signal negative sentiment from an executive.
Potential modest increase in share supply could exert slight downward pressure on AUPH.
Settlement removes immediate generic competition risk, supporting short‑term upside.
Settlement removes generic competition risk, supporting price target increase.
The settlement extends market exclusivity, likely supporting near-term upside and reducing dilution risk.
alphai scores every news story that mentions AUPH with an AI model for sentiment and relevance, and aggregates insider trades from Aurinia Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $AUPH
Score
Robertson Stephen P. sold $356K of AUPH
Robertson Stephen P. (Chief Legal Officer) sold 20,975 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 ($0.36M total) on 2026-08-21.
1 min readAurinia (NASDAQ: AUPH) officer to sell 47,000 shares for taxes
Aurinia Pharmaceuticals (AUPH) officer Stephen P. Robertson plans to sell 47,000 shares under Rule 144 to cover tax obligations from vesting performance stock units, with the sale expected to occur on or after 08/21/2026. The transaction will be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
1 min readAurinia Pharmaceuticals (AUPH) After The Teva Settlement Is The Stock A Bargain
Aurinia Pharmaceuticals (AUPH) settled with Teva, delaying generic competition for voclosporin until 2036. AUPH shares rose 13.77% in 7 days, 12.51% YTD, closing at $17.27. Revenue is projected to grow 16-21% this year, with EPS potentially doubling. The stock is considered 17.8% undervalued with a fair value of $21.00, but faces risks like concentration around Lupkynis.
2 min read
After Moderna’s Big News, Here Are Three Biotechs to Watch
Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.
3 min read
Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036
Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.
2 min read
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.
2 min read
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug - Aurinia Pharmaceuticals
Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), with Teva agreeing to not launch its generic voclosporin product until Dec. 7, 2036. Aurinia's Lupkynis is the first FDA-approved oral therapy for lupus nephritis. AUPH shares rose 2.66% premarket to $16.60, trading above its 20-day SMA of $15.31.
2 min readAurinia stock falls on Teva patent settlement for voclosporin
Aurinia Pharmaceuticals (AUPH) shares fell 2% after announcing a patent settlement with Teva (TEVA) for generic voclosporin, allowing Teva to launch its version no earlier than 2036. The agreement validates Aurinia's patents and resolves litigation. Voclosporin is marketed as LUPKYNIS for lupus nephritis. Aurinia continues patent actions against other companies.
4 min read
Trump's 200% tariffs on imported generic medicines to test India's edge
Trump proposed tariffs on imported generic medicines, with zero duties for two years from Aug 1, 2026, then 100% from Aug 1, 2028, and 200% from Aug 1, 2029, aiming to spur US manufacturing. Executives said building capacity would take at least five years. Indian pharma stocks fell on the BSE; Lupin -4.2%, Aurobindo -2%, Dr Reddy’s -2%.
6 min read
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress
Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 and first-half 2026 results. Total revenue rose to $83.2M and $160.9M, and net product sales of LUPKYNIS increased to $79.4M and $153.0M. Net income was $37.4M and $71.8M. Cash and investments were $443.1M at June 30, 2026. 2026 guidance: revenue $315M-$325M, net product sales $305M-$315M. It also initiated the PRESERVE Phase 4 study of LUPKYNIS plus biologics.
5 min read